2021 AABB Annual Meeting On-Demand

Oct 17, 2021 ‐ Oct 19, 2021


Access to the 2021 AABB Annual Meeting On-Demand sessions expires on December 31, 2023. Each session includes the on-demand recording and a downloadable MP3 audio file. Closed captioning in Spanish and English also available for most sessions. Some speaker handouts may be available, but in general, presentation handouts are not available/included.



Sessions

AM21-32: Incorporating Clinical Cellular Therapy Laboratory Education Experiences into Graduate Medical Education (GME) Training

Oct 18, 2021 3:45pm ‐ Oct 18, 2021 4:45pm

Credits: None available.

Clinical cell therapy laboratories (CTLs) that minimally manipulate products are part of many transfusion medicine (TM) services overseen by CTL medical directors with graduate medical education (GME) training in clinical pathology (CP) and/or blood banking and transfusion medicine (BB/TM). Educational experiences combining clinical CTL staff, medical director, and quality and regulatory team perspectives can provide a well-rounded approach for potential future medical directors of clinical CTLs or TM services handling existing and developing cell therapies in the clinical realm. The success and trajectory of established and novel cell therapies and nature of CP and BB/TM training to prepare medical directors underscores the importance of including formal and dedicated educational CTL experiences in CP and BB/TM training programs. This session will highlight the importance of and considerations for incorporating clinical CTL education into post-graduate medical training programs.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Learning Objectives:
  • Identify cellular therapy laboratory concepts that warrant integration into clinical pathology and/or blood banking/transfusion medicine graduate medical education
  • Describe approaches to incorporating clinical cellular therapy laboratory education into clinical pathology and/or blood banking/transfusion medicine graduate medical education
  • Discuss operational considerations when developing educational experiences for trainees in the clinical cellular therapy laboratory
Moderator & Speaker(s): Speaker(s): Disclosures
  • Sandhya Panch : Nothing to Disclose
  • Suzanne Thibodeaux, MD, PhD : Nothing to Disclose
Members: $20.00
Standard: $25.00

AM21-33: Plenary Oral Abstract Session

Oct 18, 2021 6:00pm ‐ Oct 18, 2021 7:00pm

Credits: None available.

AABB’s Selection of Abstracts Committee reserves the plenary oral abstract session for the abstracts deemed to be of the highest scientific merit and those expected to have the biggest impact on advancing the field.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Moderator(s): Speaker(s): Disclosures
  • Melissa Cushing, MD : Nothing to Disclose
  • David Green : Nothing to Disclose
Members: $20.00
Standard: $25.00

AM21-34: Late Breaking Oral Abstract Session

Oct 18, 2021 7:15pm ‐ Oct 18, 2021 8:15pm

Credits: None available.

The AABB Annual Meeting is known as the preeminent forum to present practice-changing research in transfusion medicine and biotherapies. The Late-Breaking Oral Abstract Session – returning to the annual meeting for the second time – provides an important opportunity for investigators to present novel and high-impact research that was not completed at the time of the general submission deadline.

Each of the abstracts selected for this year’s session addresses an emergent topic in transfusion medicine, such as patient outcomes based on blood donor sex and platelet bacterial detection. In addition to their impact within the field, several abstracts, such as those related to COVID-19 vaccination, also demonstrate the critical role of transfusion medicine research in supporting the pandemic response and other public health goals.

“There was no shortage of interesting and innovative research for the Committee to consider, but these abstracts address some of the most pressing questions facing our community,” said Melissa M. Cushing, MD, Selection of Abstracts Committee chair, “I look forward to this session and encourage all attendees to join me in attending.”


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Moderator(s): Speaker(s): Disclosures
  • Melissa Cushing, MD : Nothing to Disclose
Members: $20.00
Standard: $25.00

AM21-35: Leveraging the Electronic Health Record to Better Perform Hemovigilance in Hospital Based Settings

Oct 19, 2021 10:00am ‐ Oct 19, 2021 11:00am

Credits: None available.

In the US, most facilities do not participate in organized hemovigilance systems due to the large resource commitment required to conduct robust transfusion surveillance with manual data capture. This session will present two distinct systems designed to leverage the power of electronic medical records for managing hemovigilance at the hospital level. In one system, real-time monitoring of all transfusion events in a large medical oncology center is deployed as a transfusion safety backstop. In the other system data collected by both automated and “manual prospecting” approaches from the patient’s electronic health record are used for clinical alerting, bedside hemotherapy monitoring, suspected transfusion reaction investigation/reporting, and analyses for quality improvement initiatives to enhance patient safety during hemotherapy interventions. Both facilities will share their experiences and transfusion safety gains related to adopting these methods.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Learning Objectives:
  • Recognize and discuss how various electronic assets can be used by hospitals in hemovigilance activities.
  • Evaluate how the use of such assets can enhance patient care.
  • Identify how both real-time and retrospective hemovigilance monitoring approaches can advance patient safety.
Moderator(s): Speaker(s): Disclosures
  • Arthur Bracey, MD : Consultant: Verax Biomedical
  • Chester Andrzejewski, Jr., PhD, MD, FCAP : Nothing to Disclose
  • Fernando Martinez, MD, MScPH : Nothing to Disclose
Members: $20.00
Standard: $25.00

AM21-36: Oral Abstract Session -- Immunohematology and Rare Donors

Oct 19, 2021 10:00am ‐ Oct 19, 2021 11:00am

Credits: None available.

Oral abstract session focused on immunohematology and rare donors.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Learning Objectives:
  • Describe the antibody response differences seen in the abstract presented between phenotypic and genotypic matching for transfusion in patients with Sickle Cell Disease
  • Discuss the applications for using the Surface Plasmon Resonance system for IgA detection
  • Describe increased awareness of the critical importance of identifying and maintaining rare donors and knowledge of exquisitely rare types
  • Recognize the importance of using the immunohematologic test methods appropriate to the investigation of an antibody to a high prevalence antigen to resolve the antibody specificity
Moderator(s): Speaker(s): Disclosures
  • Sandra Nance, MS, MASCP, MT(ASCP)SBB : Nothing to Disclose
  • Margaret Keller, PhD : Nothing to Disclose
  • Meta Morrison : Nothing to Disclose
Members: $20.00
Standard: $25.00

AM21-37: The Dilemma of Anti - Donor Human Leukocyte Antigen Antibodies and ABO Mismatch in Allogeneic Hematopoietic Cell Transplantation

Oct 19, 2021 10:00am ‐ Oct 19, 2021 11:00am

Credits: None available.

Allogeneic hematopoietic cell transplantation (HCT) provides a curative therapeutic option for a number of hematologic diseases.

HLA mismatch has been associated with increased risks of acute graft versus host disease and inferior overall survival (OS), which nowadays can be overcome by utilizing post transplantation cyclophosphamide. Yet, a significant hinderance can occur, when the patient has developed antibodies (Ab’s) against donor HLA mismatched antigens, that can cause graft rejection and engraftment failure. This session will focus on the pathobiology of donor directed HLA Ab’s, on their clinical implications for the risk of rejection, and on current and novel Ab depletion strategies.

Major ABO donor / recipient mismatch associates with impaired engraftment, prolonged hemolysis and inferior OS. This session will focus on the pathobiology of ABO mismatches, will emphasize their clinical implications for clinical outcomes, including novel strategies beyond steroids and rituximab.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Learning Objectives:
  • Judge the clinical relevance of donor human leukocyte antigen (HLA) directed antibodies on engraftment and outcome after allogeneic hematopoietic cell transplantation (HCT)
  • Apply HLA antibody depletion strategies in the clinical setting of HLA mismatch and the presence of HLA antibodies, and will be able to discuss current and novel antibody depletion strategies.
  • Judge the clinical impact of ABO mismatch on clinical outcomes after allogeneic HCT and will be able to utilize current and novel mitigation strategies
Moderator(s): Speaker(s): Disclosures
  • Richard Maziarz, MD : Consulting/patent royalties, licensing fees: Allovir, Artiva Therapeutics, Incyte, Novartis, Athersys; Research funding: Novartis, Allovir, Bristol Meyer-Squibb, Omeros; Other: DSMB participant for Athersys, Novartis, Vor Pharma
  • Gerhard Hildebrandt, MD : Stock Shareholder (self-managed): Axim Biotechnologies, GW Pharmaceuticals, Cardinal Health, Clovis Oncology, Cellectis, CVS Health, Bluebird Bio, Pfizer, AImmune Therapeutics, Medical PPTYS TR Inc., Caretrust Reit Inc.; Consultant: Morphosys, Alexion, Karyopharm, Seatlle Genetics; Grant/Research Support: Pharmacyclics, Jazz Pharmaceuticals, Astra Zeneca
  • Reinhold Munker : Nothing to Disclose
Members: $20.00
Standard: $25.00

AM21-38: Crucial Conversations about Structural Racism, Equitable Access to Healthcare and Social Justice: Creation of a Multidisciplinary Task Force for Action

Oct 19, 2021 11:15am ‐ Oct 19, 2021 12:15pm

Credits: None available.

The emergence of the COVID-19 pandemic and its disproportionate impact on communities of color uncovered the deeply embedded structural racism that exists in the U.S. The pandemic, coupled with the highly visible murder of George Floyd that shocked the collective global consciousness, exposed the reality that structural racism and bias are global issues. We are now called to enter into deliberate dialogue about white privilege, power sharing dynamics, opening access to medical education for communities of color and delivering equitable solutions regarding the social determinants of health. With these objective in mind, in June 2020, the Academy of Integrative Health and Medicine (AIHM) successfully created The Black, Indigenous and People of Color (BIPOC) Task Force to have a role in leading this dialogue and building a coalition of diverse individuals, organizations and institutions to address these needs.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Learning Objectives:
  • Discuss the AIHM BIPOC task force experience
  • Discuss process for identifying stakeholders and strategic partnerships
  • Describe techniques for hosting virtual dialogue sessions
Moderator & Speaker(s): Speaker(s): Disclosures
  • Yvette Miller, MD, ABIHM : Nothing to Disclose
  • Celina Montemayor, MD, PhD : Nothing to Disclose
  • I. Jean Davis, PhD, PA, DC : Nothing to Disclose
Members: $20.00
Standard: $25.00

AM21-39: Optimization of Progenitor Cell Sources for Hematopoetic Cell Transplantation

Oct 19, 2021 11:15am ‐ Oct 19, 2021 12:15pm

Credits: None available.

The choice of hematopoietic progenitor cell source for transplantation is determined by multiple factors including the underlying disease (hematologic malignancy vs non-malignant hematologic disorder), conditioning regimen (myeloablative vs reduced intensity), and type of donor. Data from the prospective randomized Blood and Marrow Transplant Clinical Trial Network 0201 trial regarding bone marrow versus peripheral blood stem cell for hematopoietic cell transplantation, the declining quality of bone marrow harvests over the past two decades, and improved prevention of chronic graft versus host disease will be addressed in this context. This presentation will also address quality improvement strategies for the collection of bone marrow and innovative approaches for optimizing progenitor cell collections by apheresis, including the use of novel agents such as plerixafor and chemokine ligand 2 (CXCL2), to enhance progenitor cell yield and maximize donor safety.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Learning Objectives:
  • Describe the outcomes of the Blood and Marrow Transplant Clinical Trials Network 0201 trial
  • Discuss strategies for improving the quality of bone marrow harvests
  • Describe innovative approaches for optimizing the collection of hematopoietic progenitor cells by apheresis
Moderator & Speaker(s): Speaker(s): Disclosures
  • Laura Connelly-Smith, MD : Consultant: Alexion
  • Thomas Spitzer, MD : Adjudication Committee Member: Syneos Health, Jazz Pharmaceuticals; Scientific Advisory Board Memeber: Qihan Biotech; Data Monitoring Committee Member: Bluebird Bio
Members: $20.00
Standard: $25.00

AM21-40: Challenging Antibody Identifications in the Immunology Reference Laboratory

Oct 19, 2021 11:15am ‐ Oct 19, 2021 12:15pm

Credits: None available.

Red cell antibody identification in 95% of cases referred to Immunohematology Reference Lab is straight forward, being single, multiple, or autoantibodies. But for the remaining 5%, antibody identification is challenging, requiring the most experienced and educated minds, and the best resources for multiple serologic and molecular techniques. In these cases, resolution also means knowledge of most appropriate blood for transfusion. Complex immunohematology cases may involve unknown high prevalence antibodies, complex transfusion and transplant histories and the presence of RHD and RHCE antigen variants.
We will utilize chat boxes by pausing during critical parts to query the audience on what the next steps may be in the case.

This will be presented by recognized experts in this discipline. This event will actively engage the participants to test their skills and knowledge and will result in skill development in resolving highly complex antibody identification cases.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Learning Objectives:
  • Illustrate the process for test selection to effectively solve complex immunohematology cases
  • Describe detailed differentials for the choices of test approaches and resources
  • Utilize access to and interaction with serologic experts in the field
Moderator(s): Speaker(s):
  • Janis Hamilton, MS, MT(ASCP), SBB, American Red Cross Blood Services
  • Dr. Thierry Peyrard, PharmD, PhD, EurSpLM, Centre National de Référence pour les Groupes Sanguins, Etablissement Français du Sang Ile-de-France
Disclosures
  • Paul Mansfield, MT(ASCP), SBB : Nothing to Disclose
  • Janis Hamilton, MS, MT(ASCP), SBB : Nothing to Disclose
  • Thierry Peyrard, PharmD, PhD, EurSpLM : Nothing to Disclose
Members: $20.00
Standard: $25.00

AM21-41: Metabolic and Hemostatic Changes Contributing to Severe Disease in COVID-19 Patients

Oct 19, 2021 2:30pm ‐ Oct 19, 2021 3:30pm

Credits: None available.

Coronavirus disease 2019 (COVID-19) is a worldwide health crisis due to infection by the severe acute respiratory syndrome corona virus-2 (SARS-CoV-2). Severe COVID-19 is characterized by hypoxia, inflammation, pneumonia, and hypercoagulability. Studies suggest that COVID-19 patients are at high risk of clotting events. Other complications such as renal failure and neurological abnormalities may be due to microvascular thrombosis, and may contribute to poor patient outcomes. Proteomic and metabolomic profiling of blood from COVID-19 patients identified alterations in metabolic and complement pathways that suggest dysregulated immunomodulation, hypercoagulation, and oxygen transport and availability. Illness severity, underlying conditions, and SARS-CoV-2 infection may all contribute to these alterations and ongoing studies will help in understanding these interactions. This session describes the altered metabolic pathways and altered hemostasis that may influence disease severity.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Learning Objectives:
  • Describe how metabolomic, lipidomic, and proteomic profiling of blood is useful for identifying dysregulated pathways associated with COVID-19 that potentially contribute to severe disease.
  • Identify how metabolic changes in red blood cells modulate oxygen transport and availability in general, with possible applications to patients with COVID-19.
  • Identify mechanisms that contribute to hypercoagulability in patients with COVID-19.
Moderator(s): Speaker(s): Disclosures
  • Richard Francis, MD, PhD : Nothing to Disclose
  • Tiffany Thomas, PhD : Nothing to Disclose
  • Paul Buehler, Pharmd, PhD : Nothing to Disclose
Members: $20.00
Standard: $25.00